COVID-19: Information on ASPIRA LABS Operations

Click to Learn More
  • Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News


  • ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1

    ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1  AUSTIN, Texas, November 20, 2017 – ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), and Overa (MIA2G), today announced that the Center for Medicare Services (CMS) has released the Final 2018 Clinical Lab Fee Schedule, effective January…

  • Vermillion Announces Publication of Foundational Health Economics Study

    Vermillion Announces Publication of Foundational Health Economics Study Potential savings of up to $0.17 PMPM for Commercially Insured and $0.05 PMPM for Medicare                                             AUSTIN, Texas, November 16, 2017 — Vermillion (NASDAQ: VRML) announced today…

  • Vermillion Reports Third Quarter 2017 Results

    VRML_11 08 2017 Earnings Release in PDF form Vermillion Reports Third Quarter 2017 Results Conference Call at 4:30 p.m. ET Today AUSTIN, Texas — November 8, 2017 — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial results for the third quarter ended September 30, 2017.   Valerie Palmieri,…

  • Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum

    AUSTIN, Texas, November 6, 2017 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri, President and Chief Executive Officer, will provide a corporate overview at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum, being held at the Westin Grand Central Hotel in New York City…

  • ASPiRA Labs Announces a Major Coverage Milestone- A 27% Increase in Covered Lives for OVA1

    AUSTIN, Texas, November 1, 2017 /PRNewswire/ — ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), today announced that it has substantially expanded positive policy coverage with the addition of 14 key managed care providers. This positive coverage is a transition from negative policy to positive policy…

Investor Relations